Pre-Registration for CPHI/Hi Korea 2026: A Premier Event for Pharma and Health Innovation

CPHI/ Hi Korea 2026: A Gateway to Pharma Innovation

Informa Markets Korea has officially announced the opening of pre-registration for the much-anticipated CPHI/ Hi Korea 2026. This pivotal event is scheduled to occur at COEX, Seoul, from August 25th to 27th. This year will feature an unprecedented edition, showcasing a significant expansion across COEX Halls C, E, and The Platz, reflecting a 14% year-on-year growth in exhibition space. With approximately 420 companies from over 70 countries expected to attend, the event is poised to attract more than 12,000 industry professionals.

A Hub of International Networking

The CPHI series, a global stalwart in the pharma sector, is now making its mark in Korea, drawing stakeholders from pharma, biopharma, and nutraceutical sectors worldwide. The event presents a unique opportunity for attendees to engage in fruitful networking, fostering domestic partnerships among Korean firms while also paving the way for cross-border collaborations. At the heart of this convergence is Korea’s robust pharma manufacturing infrastructure, advanced CDMO capabilities, and a rapid growth trajectory in the nutraceutical market.

The involvement of distinguished government and industry organizations as sponsors—like the Ministry of Food and Drug Safety (MFDS) and Korea Fund for Regenerative Medicine (KFRM)—amplifies the importance of this event. Additionally, the Bio Zone is organized in collaboration with the Korea Biomedicine Industry Association (KoBIA), further emphasizing the event's strategic significance within the industry.

Expanded Conference Program

In response to an evident enthusiasm within the industry, the conference program has notably expanded from four tracks last year to six this year. Notable sessions will include discussions led by MFDS that will cover regulations pertinent to personalized health functional foods. Furthermore, attendees can participate in dedicated sessions focusing on emerging Korean technologies in the bio and pharmaceutical domains, including topics such as ADC, TPD, and RPT, along with the latest developments in GLP-1.

The lineup also features the Biohealth Policy Forum, directed by the Korea Drug Research Association (KDRA), providing invaluable insights into the trajectory of industry policies and strategic focus areas. Also included are interactive sessions geared toward investors and a Startup Challenge aimed at fostering innovation, alongside the Global Build-Up Program aimed at assisting market entry strategies across countries including Japan, China, Thailand, Malaysia, and the United States.

Urgent Call for Exhibitors

Due to overwhelming interest, Hall E has been earmarked to handle overflow demand and is rapidly approaching full capacity. Exhibitors wishing to participate are encouraged to submit their applications as soon as possible. This surge indicates the robust health of the industry and the enhanced recognition of CPHI as a leading event not just regionally but globally.

For interested attendees and exhibitors alike, early registration is now open at this link, ensuring a spot at this significant gathering of industry leaders.

With its strategic vision and strong backing, CPHI/Hi Korea 2026 promises to be a landmark event that will further drive innovation and collaboration in the health and pharmaceutical sectors across Asia and beyond.